Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 39

Results For "Centre"

1060 News Found

QMS Medical Allied Services reports 31.65% rise in Q1 FY26 PAT to Rs. 3.15 Cr
News | August 17, 2025

QMS Medical Allied Services reports 31.65% rise in Q1 FY26 PAT to Rs. 3.15 Cr

The company’s acquisition of a 51 per cent stake in Saarathi Healthcare earlier this financial year boosted growth


Vijaya Diagnostic reports Q1 FY26 consolidated PAT at Rs. 38.33 Cr
News | July 30, 2025

Vijaya Diagnostic reports Q1 FY26 consolidated PAT at Rs. 38.33 Cr

The company would be commissioning 3 hubs in Q2 FY26 across our Core Geography and West Bengal


Biocon Foundation and IISc commemorate World Head & Neck Cancer Day
News | July 29, 2025

Biocon Foundation and IISc commemorate World Head & Neck Cancer Day

This year, the OCTF focused on preparing a white paper on oral cancer elimination in India and updating its annual consensus guidelines


10.18 Cr women screened for cervical cancer under Govt. schemes
Policy | July 28, 2025

10.18 Cr women screened for cervical cancer under Govt. schemes

This achievement is part of the population-based initiative for screening, prevention, and management of Non-Communicable Diseases


AstraZeneca plans to invest $50 billion in US by 2030
News | July 22, 2025

AstraZeneca plans to invest $50 billion in US by 2030

Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US


Zigly launches its first pet hospital in Mumbai
News | July 18, 2025

Zigly launches its first pet hospital in Mumbai

The new Zigly center features and offers comprehensive veterinary services


Kenvue collaborates with API to launch India’s first cough clinics
Healthcare | July 18, 2025

Kenvue collaborates with API to launch India’s first cough clinics

Aims to support healthcare practitioners with evidence-based cough categorization tools that enable choosing the right molecules for effective & targeted relief from cough


AstraZeneca's Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial
Clinical Trials | July 14, 2025

AstraZeneca's Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial

Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo